Actionable Molecular Biomarkers in Primary Brain Tumors
- 1 July 2016
- journal article
- Published by Elsevier in Trends in Cancer
- Vol. 2 (7) , 338-349
Abstract
No abstract availableKeywords
Funding Information
- Sidney Kimmel Comprehensive Cancer Center (5P30CA006973-52)
This publication has 80 references indexed in Scilit:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Use of personalized molecular biomarkers in the clinical care of adults with glioblastomasJournal of Neuro-Oncology, 2012
- Controversies in the Adjuvant Therapy of High-Grade GliomasThe Oncologist, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005